awmsg logo



ustekinumab (Stelara®)


Reference No. 2068

Publication date:
01/04/2016


Appraisal information

ustekinumab (Stelara®) 45 mg solution for injection


Company: Janssen-Cilag Ltd
BNF category: Skin
NMG meeting date: 20/01/2016
AWMSG meeting date: 24/02/2016
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0416
Ministerial ratification: 24/03/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Ustekinumab (Stelara®) is recommended as an option for use within NHS Wales for the treatment of chronic moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download